文章摘要
刘芬,李雪,李香玉.我国新冠疫苗研制生产的监管特点分析[J].中国药事,2022,36(1):25-31
我国新冠疫苗研制生产的监管特点分析
Analysis of Regulatory Characteristics of COVID-19 Vaccine Development and Production in China
  
DOI:10.16153/j.1002-7777.2022.01.004
中文关键词: 新型冠状病毒  新冠疫苗  疫苗研制  疫苗生产  药品监管
英文关键词: SARS-CoV-2  COVID-19 vaccine  vaccine research  vaccine production  drug regulatory
基金项目:
作者单位
刘芬 上海药品审评核查中心,上海 201203 
李雪 安徽省药品审评查验中心,合肥 230051 
李香玉 上海药品审评核查中心,上海 201203 
摘要点击次数: 1268
全文下载次数: 564
中文摘要:
      目的:在我国新冠疫苗研制与生产进程加速的背景下,为加强相应的监督管理提供建议。方法: 通过查阅文献和公开信息,以及调研,梳理了国内外新冠疫苗的研制、生产与监管的现状。结果与结论:为应对新冠疫情的流行,我国加快了新冠疫苗的研制和生产进程,对此,我国药品监督管理部门与其他相关部门为保证疫苗质量和保障疫苗供应,在可供借鉴的监管经验有限的条件下,探索新冠疫苗研制和生产方面的监管机制和举措,经受了确保新冠疫苗安全有效使用的严峻考验。相对于传统的疫苗监管,新冠疫苗的研制和生产监管具有一定的新特点。
英文摘要:
      Objective: To provide suggestions for strengthening corresponding supervision and management in the context of accelerated development and production of COVID-19 vaccine in China. Methods: The current situation of the development, production and supervision of COVID-19 vaccines at home and abroad was sorted out by reviewing literature and public information. Results and Conclusion: In response to the COVID-19 pandemic, China has accelerated the development and production process of COVID-19 vaccines. In order to ensure vaccine quality and supply, drug administration department and other relevant departments have explored regulatory mechanisms and measures in the development and production of COVID-19 vaccines, with limited regulatory experience available for reference. They have withstood the severe test of ensuring the safe and effective use of COVID-19 vaccines. Compared with traditional vaccine supervision, the development and production supervision of COVID-19 vaccine has certain new features.
查看全文   查看/发表评论  下载PDF阅读器
关闭